State Street Corp Cyma Bay Therapeutics, Inc. Transaction History

State Street Corp

$2.47 Trillion
Q4 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $6.47 Million - $12.5 Million	511,972 Added 22.4%	2,797,916 $66.1 Million
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $244,882 - $397,313	-22,549 Reduced 0.98%	2,285,944 $34.1 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $12.2 Million - $18 Million	1,639,457 Added 245.05%	2,308,493 $25.3 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $1.94 Million - $3.17 Million	330,763 Added 97.78%	669,036 $5.83 Million
Q3 2022 Nov 15, 2022	SELL	$2.77 - $4.25 $66,056 - $101,349	-23,847 Reduced 6.59%	338,273 $1.18 Million
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $1.71 Million - $3.38 Million	-995,930 Reduced 73.34%	362,120 $1.07 Million
Q1 2022 May 16, 2022	BUY	$2.77 - $3.64 $66,923 - $87,942	24,160 Added 1.81%	1,358,050 $4.22 Million
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $183,861 - $261,845	56,923 Added 4.46%	1,333,890 $4.51 Million
Q3 2021 Nov 15, 2021	SELL	$3.47 - $4.42 $278,491 - $354,735	-80,257 Reduced 5.91%	1,276,967 $4.66 Million
Q2 2021 Aug 16, 2021	BUY	$3.94 - $4.92 $261,529 - $326,579	66,378 Added 5.14%	1,357,224 $5.92 Million
Q1 2021 May 17, 2021	SELL	$4.23 - $6.55 $2.19 Million - $3.39 Million	-517,501 Reduced 28.62%	1,290,846 $5.86 Million
Q4 2020 Feb 16, 2021	BUY	$5.73 - $9.03 $961,683 - $1.52 Million	167,833 Added 10.23%	1,808,347 $10.4 Million
Q3 2020 Nov 10, 2020	BUY	$3.32 - $7.24 $750,462 - $1.64 Million	226,043 Added 15.98%	1,640,514 $11.9 Million
Q2 2020 Aug 14, 2020	SELL	$1.41 - $4.25 $10,003 - $30,153	-7,095 Reduced 0.5%	1,414,471 $4.94 Million
Q1 2020 May 11, 2020	BUY	$1.25 - $2.02 $1.78 Million - $2.87 Million	1,421,566 New	1,421,566 $2.1 Million

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account